美中嘉和
CONCORD MEDICAL

CONCORD HEALTHCARE GROUP CO., LTD.
美中嘉和醫學技術發展集團股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2453)

VOLUNTARY ANNOUNCEMENT
IMPORTANT COOPERATION AGREEMENT

This announcement is made by the board of directors (the "**Board**") of Concord Healthcare Group Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis.

The Board of Directors is pleased to announce that the Company has recently formally signed a new cooperation agreement ("the **Agreement**") with the Mayo Foundation for Medical Education and Research ("**Mayo**"). Under the agreement, the Company's collaboration with Mayo will expand beyond international and standardized oncology diagnosis and treatment to encompass comprehensive life-cycle health services, including disease prevention, screening, rehabilitation, and long-term health management.

Based on the previous cooperation in proton therapy talent training, e-consultation, referral, hospital management, and international quality control, the cooperation between the two parties will be expanded from tumor diagnosis and treatment to disease prevention, screening, rehabilitation, and whole-life cycle health management. Mayo will introduce its health management service system, operational standards, and clinical experience to our company through remote planning, workshop coaching, on-site evaluation, and continuous optimization.

The board of directors believes that the agreement was entered into by the company and Mayo after fair negotiation and on general commercial terms, and that the cooperation is in the overall interests of the company and its shareholders.

REASONS FOR AND BENEFITS OF ENTERING INTO THE COOPERATION AGREEMENT

This collaboration will help our company improve the full-cycle service loop encompassing front-end preventive screening, mid-range precision diagnosis and treatment, and back-end rehabilitation management. It will enhance our medical service capabilities, operational efficiency, and patient experience, while strengthening the core competitiveness of the group. This is in line with the overall interests of our company and all shareholders.

INFORMATION OF THE PARTIES

The Company is a joint stock company with limited liability incorporated under the laws of the PRC, with its H Shares listed on the Stock Exchange on January 9, 2024. The Company is an oncology healthcare service provider in China serving both cancer patients through its self-owned medical institutions and third-party medical institutions through its medical equipment, software and related services.

Mayo is a private American academic medical center, primarily engaging in the operation of an integrated delivery healthcare system, which consists of various acute care hospitals and medical facilities, and the provision of operational consulting services.

To the best of the Company's directors ' knowledge, information and belief, Mayo and its ultimate beneficial owners are third parties independent of the Company and its connected persons (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**")).

LISTING RULES IMPLICATION

As at the date of this announcement, entering into the Agreement and the transactions contemplated thereunder do not constitute notifiable transactions or connected transactions under Listing Rules.

The Company will keep the its shareholders and potential investors of the Company informed of any further update in relation to the above by further announcement(s) made by the Company as and when appropriate in compliance with the Listing Rules.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Concord Healthcare Group Co., Ltd.
YANG Jianyu
Chairman of the Board and Executive Director

Beijing, the PRC, April 22, 2026

As at the date of this announcement, the Board comprises (i) Dr. YANG Jianyu, Ms. FU Xiao and Mr. CHANG Liang as executive Directors; (ii) Mr. WANG Lei, Mr. SONG Qingbao and Mr. SHI Botao as non-executive Directors; and (iii) Ms. LI Xuemei, Mr. SUN Yan sheng and Mr. NG Kwok Yin as independent non-executive Directors.